One of the main challenges of toxicology is the accurate prediction of compound carcinogenicity. The default test model for assessing chemical carcinogenicity, the 2 year rodent cancer bioassay, is currently criticized because of its limited specificity. With increased societal attention and new legislation against animal testing, toxicologists urgently need an alternative to the current rodent bioassays for chemical cancer risk assessment. Toxicogenomics approaches propose to use global high-throughput technologies (transcriptomics, proteomics and metabolomics) to study the toxic effect of compounds on a biological system. Here, we demonstrate the improvement of transcriptomics assay consisting of primary human hepatocytes to predict the putative liver carcinogenicity of several compounds by applying the connectivity map methodology. Our analyses underline that connectivity mapping is useful for predicting compound carcinogenicity by connecting in vivo expression profiles from human cancer tissue samples with in vitro toxicogenomics data sets. Furthermore, the importance of time and dose effect on carcinogenicity prediction is demonstrated, showing best prediction for low dose and 24 h exposure of potential carcinogens.
Introduction
For over 40 years, carcinogenic properties of both natural and synthetic compounds have been estimated using the 2 year rodent bioassay. This laborious, time consuming and expensive test kills a large number of animals. However, only 60% of its predictions are relevant for human (1) , leading to an increasing controversy on the model's usefulness (2) . Moreover, chemical manufacturing companies face an increasingly restrictive legislation against animal testing (3, 4) . Taken together, toxicology urgently needs alternative non-animal testing methods to improve compound carcinogenicity predictions. Several alternative methods already exist, such as the quantitative alternative structure relationship method, the quantum mechanics/molecular mechanics or the threshold of toxicological concern, but all feature major flaws (for reviews, see refs 5,6) .
Global gene expression profiling (i.e. transcriptomics), applied to in vitro systems representative of target organs in vivo, is also considered a putative alternative to animal testing. Some promising results, notably using the cancer liver cell line HepG2, have been obtained showing that toxicogenomic-based approaches are capable of significantly discriminating carcinogenic subclasses (7, 8) . The overall accuracy of these toxicogenomics approaches have been estimated to be around 80% for predicting in vivo toxicity in rodent (9) (10) (11) (12) (13) (14) . A recent study, based on genesets selected after stratification of chemicals combined with results from the classical Ames mutagenicity assay, reached a compound prediction accuracy of 89%, with a sensitivity of 91% and a specificity of 87% (15) . However, demonstrating the relevance of a classifying in vitro model for the human situation in vivo remains a challenge, due to the high heterogeneity of human cancers and the difficulty to build accurate cancer biomarkers.
Recently, a systematic approach referred to as 'connectivity mapping' (Cmap) was proposed to establish putative connections between a signature profile characteristic of any biological states and a core database of gene expression profiles (16) . For instance, Cmap allows the prediction of the molecular response to a new chemical entity by linking its observed effect on the gene expression profile with similar (in case of positive connection) or antagonist (negative connection) compounds. Applied to a disease state signature, Cmap may also predict whether small bioactive molecules are capable of causing or preventing this particular disease. The authors demonstrated the viability of the method with respect to several biological processes, including complex disease states such as Alzheimer disease or diet-induced obesity, be it with variable success. One of the main advantages of this method, based on the non-parametric Kolmogorov-Smirnov test, is the possibility to use any platform technology combination. Cmap has consequently been used for a variety of purposes including finding disease alternative treatments, elucidation of mode of action of drugs, drug repurposing and systems biology approaches (reviewed in ref. 17) .
In this study, we propose to exploit hepatocellular carcinoma (HCC) as a model to investigate the power of the Cmap method for predicting and classifying the putative liver carcinogenicity of a compound in vitro, the liver being the main target organ in the 2 year rodent cancer assay. HCC is the most common form of liver cancer in humans, and the third cause of cancer mortality. Liver carcinogenesis is a complex multifactor mechanism with several possible etiologies among which several viruses, such as Hepatitis B virus and Hepatitis C virus, are known to play a role, along with environmental and chemical exposures such as ethanol or aflatoxin B1 (18) . In toxicogenomics, in vitro liver systems have been well studied and multiple relevant data sets are publicly available, thus allowing the collection of sufficient data to perform a genome-wide Cmap analysis.
Materials and methods
According to the Cmap method design (16) , trying to establish a connection between liver carcinogenicity and any given compound first necessitates the building of a signature query describing the disease (in our case HCC) and of a widely ranging in vitro gene profiling 'reference' data set ( Figure 1 ).
HCC signature geneset
To establish our HCC signature geneset, we took advantage of publicly available microarray expression data sets from arrayExpress (http://www.ebi.ac.uk/ arrayexpress/) and in several steps selected the final list of genes. First, we used the Expression Project for Oncology (expO) study (E-GEOD-2109 on arrayExpress), which performed gene expression analyses on a clinically annotated set of a large panel of different tumor samples using a total of 2158 arrays. Among the 42 samples labeled as 'liver sample' in expO (each belonging to a unique donor), we selected the 10 arrays strictly identified as HCC. These 10 arrays, all hybridized on Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays, were subjected to a quality control using the ArrayAnalysis pipeline (http://www.arrayanalysis.org/), normalized by the Robust Multiarray Averaging method (for Multichip Average) and reannotated using the Custom CDF version 14 with Entrez Gene identifiers.
Second, healthy liver sample gene expression profiles generated by the same Affymetrix genechip were used as control. Three studies corresponding to these characteristics were found: E-GEOD-11045 (19) investigating three normal liver samples, E-GEOD-24042 (20) analyzing two normal liver samples and E-GEOD-15238 (21) having studied three liver samples from donors of different age (1.5, 42 and 81 years). The prenatal liver sample from the E-GEOD-15238 study was not used. All normal liver arrays were subjected to quality control and subsequently normalized and annotated similar to the cancer samples.
Reference data set
To build the reference data set, all human liver in vitro microarray data files from the Open TG_Gates database (http://toxico.nibio.go.jp/) (22) downloaded. This in vitro toxicogenomics data set presents a total of 158 compounds applied in duplicate to primary human hepatocytes (PHH) at up to three doses (low, middle and high doses) and 3 time points (2, 8 and 24 h) per compound. The high dose was determined for each compound as the maximally tolerated dose. Middle and low doses were defined by taking a concentration of 1/5 and 1/25 of the highest, respectively. Each treated compound condition is associated with a control, using PHH from the same donor. After curation, 10 compounds with inconsistent array data (missing 24 h time point condition or duplicates; Supplementary Table 1, available at Carcinogenesis Online) were removed, as well as a further nine compounds for which effects on other hepatic endpoints of toxicity than cancer were available (Supplementary Table 1 , available at Carcinogenesis Online). This curation thus resulted in a reference data set of 139 different compounds, corresponding to 2320 microarrays, all similarly generated by Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays. Each array was processed in the same way as described above for the arrays used for building the HCC signature geneset. Each treatment condition was converted into an instance reference file (as defined by Lamb et al. (16) , i.e. a treatment associated to its control pair) according to the sscMAP software protocol (23) . Briefly, each gene was associated with a score corresponding to its signed rank in the microarray global expression panel. (Table I and Supplementary Table 1, available at Carcinogenesis Online). Taking into account the two main end points for carcinogenicity of the compounds in view of the aims of this study, namely target test system (liver) and target species (human-rodents), a new classification list for hepatocarcinogenicity was created. The list consists of five groups, where two groups contain compounds with liver carcinogenic activities clearly reported on humans [carcinogenic in human liver (C HL )] or only available on rodents [carcinogenic in rodent liver (C RL )]. The group comprising of nonliver carcinogens present the known human and/or rodent carcinogenic compounds in non-liver target organs (species being distinguished by the IARC classification). The non-carcinogens (NC) group consists of established noncarcinogens in both species. Finally, the unknown carcinogenicity (UC) group comprises compounds for which no clear information is available. The final classification is presented in Table I .
Compound classification

sscMAP analysis
Connectivity between the geneset with all individual instances composing our reference data set was computed using the sscMAP JAVA software (23) . Briefly, our HCC geneset signature was used to compute a connectivity score with each reference file from the TG_Gates data set, by summing the product of each individual gene in the signature with its signed ranked in the reference file. Thus, a gene in the query described as upregulated in HCC (+1) will increase the connectivity score if this gene is upregulated in the reference (positive rank) or decrease the score if downregulated in the reference (negative rank). A P value was generated for each connectivity score using random permutation of the geneset. The analysis was carried out using the default parameter recommended by sscMAP: a number of random permutations of 10 000 (leading to a minimum P value of 10 −4 ), a random seed of 0 and an expected number of false connections to tolerate of 1. The threshold of significance was set at 1/N, with N the number of treatment instances in the reference database in the given analysis.
In order to parse the results, a scoring system was used together with plotting algorithms. The connection between the query signature and a reference instance were assessed by computing significance score (S score) for the C HL and NC compounds: S score pC pNC HL = -With pC HL and pNC representing the percentage of instances significantly and positively connected for C HL and NC, respectively. Ideally, we expect the entire C HL group compounds, our testing set, to be positively connected and above the threshold of significance after correction for multiple testing. All NC group compounds (non-liver carcinogens) are expected to be at least below this same threshold, or even negatively connected to the query. Our scoring system will give an S score of 100 for this perfect condition, and this S score will decrease for each C HL or NC compound misclassified. A score of 0 would indicate a random distribution of the various groups and a score of −100 would correspond to the extreme opposite scenario (all NC compound are significantly and positively connected to the HCC signature, and all C HL are not).
Results
HCC signature geneset composition
The HCC signature geneset was built by taking all the commonly up and downregulated genes in the 10 liver cancer samples from the expO project compared with the normal liver samples, regardless of any arbitrary cutoff threshold. The HCC final signature contained 7520 upregulated and 1414 downregulated genes that were assigned with a score of +1 for the upregulated genes and −1 for the downregulated ones (Supplementary Data 2, available at Carcinogenesis Online). We then set out to check whether the gene expressions commonly associated with HCC carcinogenesis in literature were actually present in our selected HCC signature geneset. We established a list of the 36 most commonly reported genes (Supplementary Table 3 , available at Carcinogenesis Online) from literature reviews strictly restricted to human cases combined with the EHCO II database (http://ehco.iis.sinica.edu.tw) (24): 24 genes upregulated (among which COL5A2, GPC3, MDK, TP53BP2, XPO1) and 12 downregulated (including HGFAC, IGFALS, LCAT, MT2A, SLC22A1). Surprisingly, only 40% (15/36) of those genes were found in common with our HCC signature geneset. Notably, GPC3 (glypican 3), a gene known to be overexpressed in most HCC and earlier proposed as a HCC biomarker(25), was not conserved in our signature. Although GPC3 was indeed highly expressed in five of the expO HCC cancer samples, in contrast, two samples presented a downregulation compared with the normal liver control pool, causing this particular gene to be excluded from our signature geneset.
Cmap reference data set
The reference data set was built from the in vitro human microarray data in the Open TG_Gates database (http://toxico.nibio.go.jp/) (26) , all derived from the same cell model (PHH) and microarray platform (Affymetrix hg-u133 plus 2.0). Data from 139 compounds were converted to 829 individual instances. We found clear liver carcinogenic reports in human for three compounds, i.e. ethanol, aflatoxin B1 and azathioprine, which thus defined our positive control testing group (C HL group). The full reference details of all compounds are available in Table I and Supplementary Table 1 , available at Carcinogenesis Online.
sscMAP analysis
The sscMAP analysis of our HCC signature geneset against the TG_ Gates data set produce 829 connectivity scores, one for each individual compound dose and time point. All the S scores are presented in Table II .
Plotted all together, no particularly important pattern appears (Figure 2A) . However, where the complete set fails to classify the carcinogenic compounds correctly, dividing the arrays according to experimental factors greatly improves the prediction (Table III) .
Hence, experiments using a low concentration of the compounds with an exposure duration of 24 h demonstrate the best classification, yielding a S score of 80 ( Figure 2B ). In this setting, not only the two C HL compounds (ethanol was not tested at low concentration in our reference dataset) are correctly positively connected (at the lowest P value) but also all NC compounds, except for cimetidine, are significantly negatively connected (thus a total of 85.7% compound correctly classified). The rodent hepatocarcinogenic compounds (C RL ), for which no data on human carcinogenicity are available, are represented here characterized by their available IARC (Agency for Research on Cancer) classification. The highest connectivity score comes from azathioprine, a C HL compound, followed by omeprazole (UC) and by cyclosporine A that represents the only C RL compound classified as IARC group 1 (a group of 111 agents reported to be carcinogenic to humans, independently of tissue specificity) in this setting. Several other C RL compounds with lower (or no) classification in IARC also yield a significantly high positive connection score, like methapyrilene, thioacetamide and ethinylestradiol, tending to prove a possible carcinogenic role in human liver. However, three C RL compounds (phenytoin, phenobarbital and gemfibrozil) with demonstrated carcinogenicity in rodent are negatively connected to the in vivo human signature and thus could be questioned regarding their carcinogenicity in humans. Globally, we observed that the classification improves when the dose decreases at 24 h exposure (Table II) .
The lowest S score (−26,6 ) is observed at high-dose concentration and 8 h exposure (Figure 2C ), indicating that here, several NC compounds are positively connected with HCC. Hence, at this concentration and exposure time a positive connection for 66.7% (10 of 15) of the NC compounds is displayed. This tendency toward misclassification decreases with time but remains at the level of 40% (6 out of 15) for the NC compounds after 24 h of exposure ( Figure 2D ). The same observation but with less amplitude is made for the medium concentration.
Geneset validation
In order to validate predictions of hepatocarcinogenic properties in vitro based on our in vivo HCC signature geneset, we used in vitro toxicogenomic data from two compounds, tested in-house also in PHH: aflatoxin B1, a C HL compound also present in the TG_Gates data set, and Benzo[a]pyrene, an IARC group 1 compound known for its hepatocarcinogenicity in mice. This validation data set has been generated similarly to the study protocol of the TG_Gates assays (three doses, Affymetrix platform, PHH) but has been derived only after one exposure period (24 h). Those data were added to our reference data set, and a new sscMAP analysis was performed (Figure 3) . Interestingly, the resulting data set generated a significant positive connection at all experimental condition for aflatoxin B1, similarly as obtained for aflatoxin using the TG_Gates data set, thus confirming the high potential of aflatoxin B1 for inducing liver carcinogenicity. However, the scores from our data set are always higher. Benzo[a]pyrene displays a significant positive connection when using data from both low-and high-incubation concentrations. Data obtained upon BaP exposure at 
Discussion
Here, we studied the reliability of the Cmap method for classifying and predicting a compound's hepatocarcinogenicity. To reduce all possible variables, the study was performed on a single cancer type (HCC) and used a unique liver cell model (PHH) exposed to a wide range of different compounds, of which some were known human liver carcinogens (C HL ) and some known non-liver carcinogens. Using the sscMap software, our Cmap analysis establishes significantly positive connections with all hepatocarcinogens available in the TG_Gates data set at low concentration and at 24 h of exposure, and a negative connection with all but one of the NC compounds at this same concentration.
Most of the Cmap studies used the Cmap data set available at the Broad Institute (www.broadinstitute.org/cmap) as a reference set. Cmap reference data set contains more than 7000 expression profiles representing 1309 compounds used on five different cultured human cancer cell lines (MCF7, ssMCF7, HL60, PC3 and SKMEL5). We decided not to use this reference data set as none of the five cell lines are related to liver and thus the Cmap reference data set is not optimized for liver carcinogenicity prediction.
Interestingly, our signature geneset, based on an in vivo liver cancer expression profile, contains many more genes than usual biomarker lists representing a biological signature. However, with a geneset of 8934 genes (7520 upregulated and 1414 downregulated) selected without any expression threshold, the advantage is that we were able to keep all small genes expression variations observed 'in liver' cancer samples in vivo. Internal testing with many different lists of genes usually linked to HCC in literature and databases failed to establish any significant connection with the C HL compounds (data not shown). We believe this could be explained by the complexity of the carcinogenic mechanisms that cannot be resumed within a small list of biomarker genes. This observation supports the debate on the difficulty to define effective biomarkers for cancer (27, 28) . The ability of Cmap methodology to virtually use an unlimited amount of genes to define a signature seems, however, to be a powerful asset in carcinogenicity prediction.
Importantly, our reference set (and validating set) used only PHH, a non-cancer cell model, and thus our positive connection using in vivo cancer signature, cannot be biased by deviations in normal expression patterns resulting from the common criteria with the cancer phenotype, as the immortal state. Indeed, we tried to mix PHH assays with HepG2 cells assays to build our reference data set and observed that HepG2 assays were globally more connected to querydefined HCC states than PHH assays, independently of the compound carcinogenicity classification (data not shown). To avoid this putative bias, and because our ultimate goal is to find an alternative in vitro method to predict carcinogenicity at the earliest possible stage, we decided to remove all liver cancer cell models and work only with PHH data.
Moreover, Cmap seems to be able to differentiate compound carcinogenicity based on their incubation concentration in vitro. Thus, our signature geneset better classifies the known human hepatocarcinogens (C HL ) at low concentration in vitro than at high concentration. More importantly, a higher number of false positives appear at high dose for NC compounds. These results underline the importance of applying low exposures in in vitro toxicological assays for predicting genotoxicity and carcinogenicity, in order to avoid possible cytotoxic dose responses. Unfortunately, the low-concentration condition is missing for several compounds in the TG_Gates database. It would be interesting to add more compounds, both known human liver carcinogens and non-carcinogens, to our reference set to see how this query would behave.
Since our best setting to predict carcinogenicity is at low compound concentration and after 24 h of exposure, evaluating connectivity to the HCC signature of compounds with unknown carcinogenic properties (UC group) at this setting may be quite informative. Of the 36 compounds in the TG_Gates data set within the UC group and tested at low concentration, 10 are significantly positively connected with our query: omeprazole, diclofenac, glibenclamide, carbamazepine, triazolam, N-nitrosomorpholine, naphthyl isothiocyanate, propranolol, methyltestosterone, amphotericin B, buthionine sulfoximine and diethyl maleate (listed here in order of decreasing connectivity score). However, as those compounds are mainly drugs used for diverse applications, some of them could have been taken by the patient associated with the liver cancer samples. For instance, omeprazole, a proton pump inhibitor, is one of the most widely prescribed drugs internationally. Diclofenac is often used to treat chronic pain associated with cancer, and thus may have induced a change of expression in the patient's liver, correlated with the gene expression induced by this compound in the in vitro TG_Gates and then inducing a connection between the two profiles. The complete donor drug prescription would be necessary to sort out the real carcinogenic compound from the false positive.
Another possible way to increase prediction accuracy would be to use other types of 'omics' information in the reference dataset such Each row corresponds to a microarray using a given compound, at low concentration and at 24 h exposure. The connectivity score (setscore) and the corresponding P value are given. A significance mark of 1 indicates significance above the threshold corrected for multiple testing. Table III . Continued as proteomics, thus increasing the amount of possible connections. Indeed, in view of the fact that the Cmap method essentially is a nonparametric method, complementing transcriptomics results with data on proteomics and/or metabolomics experiments derived from the same samples, may bring added value. All those connections could then be integrated in a putative model predicting cancer pathways and, consequently, may allow a better carcinogenicity prediction. In order to achieve such cross-omics analyses, the Toxicogenomics community would benefit from a central database to regroup all the available experiments. Several international projects, including the European diXa project (http://www.dixa-fp7.eu/), work in this direction.
To conclude, we believe that the Cmap methodology offers an interesting perspective of how to predict a compound's carcinogenicity based on data from representative in vitro models by adding relevance for human disease end points to the prediction model and may be considered as a classification method for new compounds
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